-
近十年来,随着对生长抑素(somatostatin, SST)研究的日趋深入,发现生长抑素受体(somatostatin receptor, SSTR)不仅分布在正常SST靶组织内,而且在这些组织的病变(肿瘤组织及其转移灶)中也存在不同程度的表达[1-3],甚至高于在正常组织中的表达[4]。因此,可以利用其与SST及其类似物(如奥曲肽)的高亲和力,从分子水平上对SSTR进行定位和显像。目前,临床上常用的影像学方法如超声、CT、MRI等,一般可发现直径约1~3 cm的肿块,但对于较小的肿瘤其检查意义不大[5]。而SPECT受体显像是从分子水平上来进行显像,在早期就可以发现SSTR高表达的病灶,尤其对神经内分泌肿瘤等较小病灶的敏感性较高。这对SSTR阳性肿瘤的诊断、分期及预后评价具有较为重要的临床价值,可作为常规影像学检查的一种有力补充,并且这已成为当今核医学领域的主要检查内容之一。
生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究
Development of study on SPECT imaging with radioisotope 99Tcm-octreotide
-
摘要: 核医学SPECT在20世纪已进入分子显像时代,受体显像尤其是生长抑素受体显像更是目前核医学显像研究的热点。利用111In、123I、99Tcm、90Y等放射性核素标记生长抑素类似物奥曲肽进行生长抑素受体显像的方法,已经比较成熟,且部分已用于临床显像。该文对99Tcm标记奥曲肽的方法(直接法、间接法)、99Tcm-奥曲肽SPECT显像方法及其临床应用等作简要概述。
-
关键词:
- 奥曲肽 /
- 受体,生长抑素 /
- 锝化合物 /
- 体层摄影术, 发射型计算机, 单光子
Abstract: The development of single photon emission computed tomography imaging has stepped into a molecular level since the last century. Receptor imaging has been one of hotspots in the current nuclear medicine imaging research, especially the somatostatin receptor scintigraphy. Octreotide, a frequently used somatostatin receptor in the clinic, has been labeled with lots of radioisotopes such as 111In, 123I, 99Tcm, 90Y. Earlier studies have demonstrated that the direct and indirect labelling methods of 99Tcm-octreotide have been relatively mature and have a high labeling efficiency. And SPECT imaging with 99Tcm-octreotide has a high accuracy in finding somatostatin receptor-positive lesions especially gastrointestinal neuroendocrine tumors. 99Tcm-octreotide, a promising somatostatin receptor imaging agent, will be widely used for clinical imaging. -
[1] Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med, 2000, 41(10): 1704-1713. [2] Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch, 2001, 439(6): 787-797. [3] Rabinowitz I, Telepak R, Lee FC. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma. Clin Nucl Med, 2002, 27(7): 499-502. [4] Reubi JC. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology, 2004, 80 Suppl 1:51-56. [5] Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab, 2005, 19(2): 265-276. doi: 10.1016/j.beem.2004.11.016 [6] Gotthardt M, Behe MP, Alfke H, et al. Imaging lung tumors with peptide-based radioligands. Clin Lung Cancer, 2003, 5(2): 119-124. [7] Hofland LJ, Lamberts SW, van Hagen PM, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med, 2003, 44(8): 1315-1321. [8] Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci, 1982, 31(11): 1133-1140. [9] 王丽华, 汪勇先, 尹端沚.生长抑素及其类似物的标记技术的发展.核技术, 2003, 26(7): 537-544. doi: 10.3321/j.issn:0253-3219.2003.07.012
[10] 徐文贵, 马庆杰, 张建中, 等.肿瘤特异性受体显像剂Octreotide(奥曲肽)的99Tcm标记与纯化方法研究.中国老年学杂志, 2004, 24(12): 1133-1134. doi: 10.3969/j.issn.1005-9202.2004.12.017
[11] 武凤玉, 左书耀.放射性核素标记奥曲肽肿瘤受体显像研究进展.国外医学肿瘤学分册, 2005, 32(10): 760-763.
[12] 武鸿文, 管昌田, 梁正路, 等.肿瘤生长抑素受体显像剂99Tcm-octreotide的制备及鉴定.中华核医学杂志, 2000, 20(3): 112-116. doi: 10.3760/cma.j.issn.2095-2848.2000.03.005
[13] 武鸿文, 管昌田, 梁正路. 99Tcm直接法标记Octreotide.同位素, 2000, 13(3): 152-156. doi: 10.3969/j.issn.1000-7512.2000.03.005
[14] 王叙馥, 左书耀, 邵文博, 等.肿瘤受体显像剂99Tcm-octreotide的放化纯度分析.同位素, 2003, 16(01): 26-29. doi: 10.3969/j.issn.1000-7512.2003.01.006
[15] 章斌. 188Re直接标记octreotide的方法学.国外医学放射医学核医学分册, 2002, 26(5): 220-222.
[16] Thakur ML, Kolan HR, Rifat S, et al. Vapreotide label with 99mTc for imaging tumor. Int J Oncol, 1996, 6: 445-451. [17] 马庆杰, 徐文贵, 张建中, 等. SnCl2还原法生长抑素受体显像剂99Tcm-octreotide(奥曲肽)的生物活性研究.中国老年学杂志, 2004, 24(11): 1048-1049. doi: 10.3969/j.issn.1005-9202.2004.11.029
[18] 景红丽, 李方, 杜延荣, 等. 99mTc-HYNIC-TOC生长抑素受体显像诊断胰腺神经内分泌肿瘤的临床应用.胃肠病学, 2008, 13(4): 195-199. doi: 10.3969/j.issn.1008-7125.2008.04.002
[19] 王胜军, 汪静, 邓敬兰, 等. 99Tcm-HYNIC-Octreotide的标记及其在脑膜瘤诊断中的初步应用.中国临床医学影像杂志, 2008, 19(8): 551-554. doi: 10.3969/j.issn.1008-1062.2008.08.006
[20] 邓念英, 张金山, 冼有卿. 99mTc-奥曲肽和99mTc-MIBI显像在乳腺癌临床的应用价值.中国普外基础与临床杂志, 2004, 11(1): 17-19. doi: 10.3969/j.issn.1007-9424.2004.01.007
[21] 段炼, 李险峰, 陆克义, 等. 99Tcm-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用.中华眼科杂志, 2006, 42(12): 1068-1072. doi: 10.3760/j:issn:0412-4081.2006.12.004
[22] 武鸿文, 管昌田, 李云春. 99mTc-octreotide的动物体内分布、药物动力学和临床初步应用研究.华西医科大学学报, 2000, 31(4): 481-484.
[23] 王佳琼, 王自正, 姚薇萱, 等. 99mTc-MIBI与99mTc-Octreotide生长抑素受体显像诊断乳腺癌的对比研究.中国医学影像学杂志, 2006, 14(2): 91-93. doi: 10.3969/j.issn.1005-5185.2006.02.004
[24] Cwikla J B, Mikolajczak R, Pawlak D, et al. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med, 2008, 49(7): 1060-1065. doi: 10.2967/jnumed.107.046961 [25] Gomez M, Ferrando R, Vilar J, et al. 99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract. Acta Gastroenterol Latinoam, 2010, 40(4): 332-338. [26] Jing H, Li F, Chen L, et al. Detection of recurrent pancreatic primitive neuroectodermal tumor by tc-99m hydrazinonicotinyl-tyr3-octreotide scan. Clin Nucl Med, 2011, 36(1): 54-55. [27] Sepulveda-Mendez J, de Murphy CA, Pedraza-Lopez M, et al. Specificity and sensitivity of 99mTc-EDDA/HYNIC-Tyr(3)-oc-treotide (99mTc-TOC) for imaging neuroendocrine tumors. Nucl Med Commun, 2012, 33(1): 69-79. [28] 王峰, 王自正, 姚薇萱, 等. 99Tcm-生长抑素受体显像对肺癌的诊断价值.中华结核和呼吸杂志, 2005, 28(4): 218-220. doi: 10.3760/j:issn:1001-0939.2005.04.002
[29] 王叙馥.放射性核素标记奥曲肽诊断小细胞肺癌的研究进展.国外医学放射医学核医学分册, 2003, 27(1): 11-13.
[30] Nocun A, Chrapko B, Golebiewska R, et al. Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy. Nucl Med Commun, 2011, 32(6): 522-529. [31] 何小江, 黄劲雄, 陈贵兵, 等. 99mTc-奥曲肽显像和X线钼靶诊断乳腺癌.中国医学影像技术, 2009, 25(10): 1892-1895. doi: 10.3321/j.issn:1003-3289.2009.10.044
[32] Chen L, Li F, Zhuang H, et al. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. J Nucl Med, 2009, 50(3): 397-400. [33] Czepczynski R, Kosowicz J, Mikolajczak R, et al. New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma. Pol Arch Med Wewn, 2006, 116(3): 853-860. [34] Kurtaran A, Scheuba C, Kaserer K, et al. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. J Nucl Med, 1998, 39(11): 1907-1909. [35] 赵德善, 乔振华, 张伟华, 等. 99Tcm-奥曲肽显像在淋巴瘤诊断中的应用.中华核医学杂志, 2007, 27(4): 224-226. doi: 10.3760/cma.j.issn.2095-2848.2007.04.009
[36] 吴培仁, 何小江, 许林, 等. 99Tcm奥曲肽核素显像诊断结直肠癌的研究.中华肿瘤防治杂志, 2010, 17(5): 381-383.
[37] Gambini JP, Lopez LJ, Quagliata A, et al. 99mTc-HYNIC octreotide in neuroblastoma. Ann Nucl Med, 2008, 22(9): 817-819. doi: 10.1007/s12149-008-0201-9 [38] Kukwa W, Andrysiak R, Kukwa A, et al. 99mTc-octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasop-haryngeal angiofibromas. Head Neck, 2011, 33(12): 1739-1746. doi: 10.1002/hed.21668 [39] 李眉, 戴皓洁, 王雪, 等. 99mTc-奥曲肽SPECT/CT评价甲状腺相关性眼病活动期.中国医学影像技术, 2011, 27(3): 505-509.
[40] Sun H, Jiang XF, Wang S, et al. 99mTc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy(GO). Endocrine, 2007, 31(3): 305-310. [41] 蔡胜, 袁岩, 姜玉新, 等.瘤原性佝偻病致病肿瘤的影像定位诊断.中国医学影像技术, 2006, 22(12): 1873-1876. doi: 10.3321/j.issn:1003-3289.2006.12.028
[42] 张化冰, 潘慧, 李方, 等.奥曲肽显像诊断肿瘤性骨软化一例.中华医学杂志, 2005, 85(33): 2375-2376. doi: 10.3760/j:issn:0376-2491.2005.33.020
计量
- 文章访问数: 2699
- HTML全文浏览量: 1848
- PDF下载量: 9